Globus Medical (GMED)
(Delayed Data from NYSE)
$50.55 USD
+0.18 (0.36%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $50.57 +0.02 (0.04%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GMED 50.55 +0.18(0.36%)
Will GMED be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GMED based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GMED
GMED vs. PEN: Which Stock Is the Better Value Option?
Why Globus Medical (GMED) is a Top Momentum Stock for the Long-Term
GMED: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Globus Medical (GMED) is a Top Momentum Stock for the Long-Term
Globus Medical (GMED) Gains From New Launches Amid Macro Issues
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Other News for GMED
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Globus Medical (GMED) and Merck & Company (MRK)
Interesting GMED Put And Call Options For December 20th
RBC Capital Sticks to Its Buy Rating for Globus Medical (GMED)
Globus Medical Schedules First Quarter Earnings Release and Conference Call
What's Driving Masimo Corp's Surprising 17% Stock Rally?